ArrowMark Colorado Holdings LLC Sells 524,990 Shares of Sotera Health (NASDAQ:SHC)

ArrowMark Colorado Holdings LLC lessened its holdings in shares of Sotera Health (NASDAQ:SHC) by 13.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,373,767 shares of the company’s stock after selling 524,990 shares during the period. ArrowMark Colorado Holdings LLC owned about 1.19% of Sotera Health worth $56,342,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Darsana Capital Partners LP grew its stake in shares of Sotera Health by 716.9% in the 3rd quarter. Darsana Capital Partners LP now owns 20,010,000 shares of the company’s stock valued at $334,167,000 after buying an additional 17,560,636 shares during the period. Sessa Capital IM L.P. raised its position in Sotera Health by 46.5% in the third quarter. Sessa Capital IM L.P. now owns 6,300,597 shares of the company’s stock worth $105,220,000 after acquiring an additional 2,000,000 shares during the period. Maverick Capital Ltd. increased its holdings in Sotera Health by 3.5% in the 3rd quarter. Maverick Capital Ltd. now owns 3,497,367 shares of the company’s stock worth $58,406,000 after acquiring an additional 118,353 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Sotera Health by 18.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,348,917 shares of the company’s stock worth $22,527,000 after purchasing an additional 208,914 shares in the last quarter. Finally, William Blair Investment Management LLC grew its stake in Sotera Health by 0.6% in the 2nd quarter. William Blair Investment Management LLC now owns 1,131,455 shares of the company’s stock valued at $13,430,000 after buying an additional 6,707 shares in the last quarter. Institutional investors and hedge funds own 91.03% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on SHC. Barclays increased their price objective on Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, August 6th. Citigroup increased their target price on shares of Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $17.00 price objective on shares of Sotera Health in a research note on Thursday, November 21st. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $16.50.

Insider Activity at Sotera Health

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the company’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $15.03, for a total value of $150,300,000.00. Following the completion of the sale, the director now owns 49,215,301 shares in the company, valued at $739,705,974.03. This represents a 16.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 55.12% of the stock is owned by company insiders.

Sotera Health Stock Up 0.5 %

Shares of Sotera Health stock opened at $13.17 on Monday. The stock has a market capitalization of $3.73 billion, a PE ratio of 52.68 and a beta of 2.08. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. The company has a 50-day simple moving average of $15.25 and a two-hundred day simple moving average of $14.04. Sotera Health has a 52-week low of $10.71 and a 52-week high of $17.44.

Sotera Health (NASDAQ:SHC) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. The business had revenue of $285.47 million during the quarter, compared to analysts’ expectations of $278.64 million. During the same quarter in the prior year, the firm earned $0.18 EPS. The firm’s revenue for the quarter was up 8.5% compared to the same quarter last year. On average, analysts anticipate that Sotera Health will post 0.61 EPS for the current fiscal year.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.